Cargando…

Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab

The aim of this study was to assess the utility of neutrophil-to-lymphocyte ratio (NLR), plate-let-to-lymphocyte ratio (PLR), and systemic immune inflammation index (SII) as predictive biomarkers with oncological outcomes for metastatic renal cell carcinoma (mRCC) patients treated with nivolumab and...

Descripción completa

Detalles Bibliográficos
Autores principales: Iinuma, Koji, Enomoto, Torai, Kawada, Kei, Fujimoto, Shota, Ishida, Takashi, Takagi, Kimiaki, Nagai, Shingo, Ito, Hiroki, Kawase, Makoto, Nakai, Chie, Kawase, Kota, Kato, Daiki, Takai, Manabu, Nakane, Keita, Kameyama, Koji, Koie, Takuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8617687/
https://www.ncbi.nlm.nih.gov/pubmed/34830607
http://dx.doi.org/10.3390/jcm10225325
_version_ 1784604565583167488
author Iinuma, Koji
Enomoto, Torai
Kawada, Kei
Fujimoto, Shota
Ishida, Takashi
Takagi, Kimiaki
Nagai, Shingo
Ito, Hiroki
Kawase, Makoto
Nakai, Chie
Kawase, Kota
Kato, Daiki
Takai, Manabu
Nakane, Keita
Kameyama, Koji
Koie, Takuya
author_facet Iinuma, Koji
Enomoto, Torai
Kawada, Kei
Fujimoto, Shota
Ishida, Takashi
Takagi, Kimiaki
Nagai, Shingo
Ito, Hiroki
Kawase, Makoto
Nakai, Chie
Kawase, Kota
Kato, Daiki
Takai, Manabu
Nakane, Keita
Kameyama, Koji
Koie, Takuya
author_sort Iinuma, Koji
collection PubMed
description The aim of this study was to assess the utility of neutrophil-to-lymphocyte ratio (NLR), plate-let-to-lymphocyte ratio (PLR), and systemic immune inflammation index (SII) as predictive biomarkers with oncological outcomes for metastatic renal cell carcinoma (mRCC) patients treated with nivolumab and ipilimumab (NIVO + IPI). We conducted a retrospective multicenter cohort study assessing patients with mRCC treated with NIVO + IPI at eight institutions in Japan. In this study, the follow-up period was median 14 months. The 1-year overall- and progression-free survival (PFS) rates were 89.1% and 63.1, respectively. The objective response rate (ORR) and disease control rate (DCR) were 41.9% and 81.4%, respectively. The 1-year PFS rates were 85.7% and 49.1% for NLR ≤ 2.8 and >2.8, respectively (p = 0.005), and 75.5% and 49.7% for PLR ≤ 215.6 and >215.6, respectively (p = 0.034). Regarding SII, the 1-year PFS rates were 90.0% and 54.8% when SII was ≤561.7 and >561.7, respectively (p = 0.023). Therefore, NLR, PLR, and SII levels in mRCC patients treated with NIVO + IPI may be useful in predicting oncological outcomes.
format Online
Article
Text
id pubmed-8617687
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86176872021-11-27 Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab Iinuma, Koji Enomoto, Torai Kawada, Kei Fujimoto, Shota Ishida, Takashi Takagi, Kimiaki Nagai, Shingo Ito, Hiroki Kawase, Makoto Nakai, Chie Kawase, Kota Kato, Daiki Takai, Manabu Nakane, Keita Kameyama, Koji Koie, Takuya J Clin Med Article The aim of this study was to assess the utility of neutrophil-to-lymphocyte ratio (NLR), plate-let-to-lymphocyte ratio (PLR), and systemic immune inflammation index (SII) as predictive biomarkers with oncological outcomes for metastatic renal cell carcinoma (mRCC) patients treated with nivolumab and ipilimumab (NIVO + IPI). We conducted a retrospective multicenter cohort study assessing patients with mRCC treated with NIVO + IPI at eight institutions in Japan. In this study, the follow-up period was median 14 months. The 1-year overall- and progression-free survival (PFS) rates were 89.1% and 63.1, respectively. The objective response rate (ORR) and disease control rate (DCR) were 41.9% and 81.4%, respectively. The 1-year PFS rates were 85.7% and 49.1% for NLR ≤ 2.8 and >2.8, respectively (p = 0.005), and 75.5% and 49.7% for PLR ≤ 215.6 and >215.6, respectively (p = 0.034). Regarding SII, the 1-year PFS rates were 90.0% and 54.8% when SII was ≤561.7 and >561.7, respectively (p = 0.023). Therefore, NLR, PLR, and SII levels in mRCC patients treated with NIVO + IPI may be useful in predicting oncological outcomes. MDPI 2021-11-16 /pmc/articles/PMC8617687/ /pubmed/34830607 http://dx.doi.org/10.3390/jcm10225325 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Iinuma, Koji
Enomoto, Torai
Kawada, Kei
Fujimoto, Shota
Ishida, Takashi
Takagi, Kimiaki
Nagai, Shingo
Ito, Hiroki
Kawase, Makoto
Nakai, Chie
Kawase, Kota
Kato, Daiki
Takai, Manabu
Nakane, Keita
Kameyama, Koji
Koie, Takuya
Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab
title Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab
title_full Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab
title_fullStr Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab
title_full_unstemmed Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab
title_short Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab
title_sort utility of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and systemic immune inflammation index as prognostic, predictive biomarkers in patients with metastatic renal cell carcinoma treated with nivolumab and ipilimumab
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8617687/
https://www.ncbi.nlm.nih.gov/pubmed/34830607
http://dx.doi.org/10.3390/jcm10225325
work_keys_str_mv AT iinumakoji utilityofneutrophiltolymphocyteratioplatelettolymphocyteratioandsystemicimmuneinflammationindexasprognosticpredictivebiomarkersinpatientswithmetastaticrenalcellcarcinomatreatedwithnivolumabandipilimumab
AT enomototorai utilityofneutrophiltolymphocyteratioplatelettolymphocyteratioandsystemicimmuneinflammationindexasprognosticpredictivebiomarkersinpatientswithmetastaticrenalcellcarcinomatreatedwithnivolumabandipilimumab
AT kawadakei utilityofneutrophiltolymphocyteratioplatelettolymphocyteratioandsystemicimmuneinflammationindexasprognosticpredictivebiomarkersinpatientswithmetastaticrenalcellcarcinomatreatedwithnivolumabandipilimumab
AT fujimotoshota utilityofneutrophiltolymphocyteratioplatelettolymphocyteratioandsystemicimmuneinflammationindexasprognosticpredictivebiomarkersinpatientswithmetastaticrenalcellcarcinomatreatedwithnivolumabandipilimumab
AT ishidatakashi utilityofneutrophiltolymphocyteratioplatelettolymphocyteratioandsystemicimmuneinflammationindexasprognosticpredictivebiomarkersinpatientswithmetastaticrenalcellcarcinomatreatedwithnivolumabandipilimumab
AT takagikimiaki utilityofneutrophiltolymphocyteratioplatelettolymphocyteratioandsystemicimmuneinflammationindexasprognosticpredictivebiomarkersinpatientswithmetastaticrenalcellcarcinomatreatedwithnivolumabandipilimumab
AT nagaishingo utilityofneutrophiltolymphocyteratioplatelettolymphocyteratioandsystemicimmuneinflammationindexasprognosticpredictivebiomarkersinpatientswithmetastaticrenalcellcarcinomatreatedwithnivolumabandipilimumab
AT itohiroki utilityofneutrophiltolymphocyteratioplatelettolymphocyteratioandsystemicimmuneinflammationindexasprognosticpredictivebiomarkersinpatientswithmetastaticrenalcellcarcinomatreatedwithnivolumabandipilimumab
AT kawasemakoto utilityofneutrophiltolymphocyteratioplatelettolymphocyteratioandsystemicimmuneinflammationindexasprognosticpredictivebiomarkersinpatientswithmetastaticrenalcellcarcinomatreatedwithnivolumabandipilimumab
AT nakaichie utilityofneutrophiltolymphocyteratioplatelettolymphocyteratioandsystemicimmuneinflammationindexasprognosticpredictivebiomarkersinpatientswithmetastaticrenalcellcarcinomatreatedwithnivolumabandipilimumab
AT kawasekota utilityofneutrophiltolymphocyteratioplatelettolymphocyteratioandsystemicimmuneinflammationindexasprognosticpredictivebiomarkersinpatientswithmetastaticrenalcellcarcinomatreatedwithnivolumabandipilimumab
AT katodaiki utilityofneutrophiltolymphocyteratioplatelettolymphocyteratioandsystemicimmuneinflammationindexasprognosticpredictivebiomarkersinpatientswithmetastaticrenalcellcarcinomatreatedwithnivolumabandipilimumab
AT takaimanabu utilityofneutrophiltolymphocyteratioplatelettolymphocyteratioandsystemicimmuneinflammationindexasprognosticpredictivebiomarkersinpatientswithmetastaticrenalcellcarcinomatreatedwithnivolumabandipilimumab
AT nakanekeita utilityofneutrophiltolymphocyteratioplatelettolymphocyteratioandsystemicimmuneinflammationindexasprognosticpredictivebiomarkersinpatientswithmetastaticrenalcellcarcinomatreatedwithnivolumabandipilimumab
AT kameyamakoji utilityofneutrophiltolymphocyteratioplatelettolymphocyteratioandsystemicimmuneinflammationindexasprognosticpredictivebiomarkersinpatientswithmetastaticrenalcellcarcinomatreatedwithnivolumabandipilimumab
AT koietakuya utilityofneutrophiltolymphocyteratioplatelettolymphocyteratioandsystemicimmuneinflammationindexasprognosticpredictivebiomarkersinpatientswithmetastaticrenalcellcarcinomatreatedwithnivolumabandipilimumab